The Food and Drug Administration (FDA) stated in a court filing on Wednesday that it will not publish its safety review of the abortion drug mifepristone until March. The agency also indicated that it will not impose any new restrictions on the drug prior to that date.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Announces Delay in Mifepristone Safety Review Until March
The FDA has announced that its safety review of mifepristone will not be completed until March. The agency confirmed that no new restrictions will be placed on the drug before the review is published.
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
FDA: Mifepristone review won’t be done until March
Neutral Headline
FDA Announces Delay in Mifepristone Safety Review Until March